The Indiana Department of Health recently approved a major hospital merger in Terre Haute between Union Health and HCA Healthcare’s Terre Haute Regional Hospital. Under traditional antitrust analysis, the transaction is the kind of horizontal consolidation that would raise serious red flags. The combined system will control nearly all inpatient hospital services in Vigo County, and the state itself acknowledged that the merger is “presumptively anticompetitive.”

Yet the deal moved forward, largely because it was evaluated not under federal merger law, but under Indiana’s Certificate of Public Advantage (COPA) framework, which allows the state to approve consolidations in exchange for price, quality, and service commitments enforced through regulatory oversight.

The decision, and the debate around it, offers a useful case study in the ongoing tension between competition policy and states’ desire to preserve access, stabilize financially strained hospitals, and maintain local control. For healthcare companies, insurers, providers, and counsel, the Indiana approval provides five important lessons.

1. COPAs Continue to Serve as an Alternative Pathway for Hospital Mergers

COPAs are not new, but they are a strategic tool in markets where federal regulators are increasingly skeptical of consolidation. Under a COPA, the state replaces competition with regulatory oversight, effectively granting the merging parties immunity from federal antitrust challenge as long as certain conditions are met.

Indiana’s approval is notable because:

  • The market is highly concentrated, with post-merger shares approaching a monopoly for key inpatient services.
  • The FTC strongly opposed the transaction, citing likely price increases, quality deterioration, and wage suppression.
  • The state nevertheless concluded that the merger’s purported benefits, including maintaining two hospital campuses, improving service lines, and stabilizing finances, would outweigh the competitive risks if robust oversight is in place.

COPAs result in the state acting as the guarantor of “competitive-like” outcomes in markets where actual competition will be lost. Whether states can realistically enforce these obligations long-term is an open question, but the Indiana approval underscores that federal opposition does not guarantee a merger will be stopped.

2. Strong Guardrails Were the Price of Approval, But Their Durability Is Unclear

To mitigate the loss of competition, the merged entity committed to a substantial set of pricing and quality conditions. The most significant: commercial rates may not exceed an average of 265% of Medicare rates for comparable services. The hospitals also must:

  • Maintain both campuses and key service lines
  • Commit to specific quality metrics and access standards
  • File regular reports to allow state monitoring
  • Operate under oversight for an initial five-year period, extendable up to ten years

These guardrails are meaningful, particularly the price cap, which provides payers with a rare, concrete benchmark. But they invite several long-term questions:

  • Enforcement challenges. Oversight regimes require resources and expertise; historically, states have struggled to enforce COPA conditions effectively.
  • Expiration risk. Once the COPA expires, local monopoly power remains. Prices and wages may rise, and service lines may contract.
  • Monitoring complexity. Enforcing caps tied to Medicare rates requires ongoing analysis of commercial mix, coding, and rate design, all areas where providers may seek flexibility.

3. Labor Market Harms Are No Longer a Secondary Consideration

An increasingly important dimension of hospital mergers is their impact on labor markets. The FTC and academic researchers highlighted that, in a market where two hospitals become one, nurses and clinical staff lose a major competitor for employment, thereby potentially suppressing wages.

A Yale-affiliated analysis estimated:

  • Nurse wages could decline by approximately 5%
  • Local job losses could result from consolidating administrative and support functions

This reflects a broader trend in antitrust enforcement: the agencies are incorporating labor effects into merger analysis, and courts are beginning to acknowledge them in other industries. Even though federal authorities objected, Indiana’s decision shows how states weigh these concerns differently. This is a key takeaway for future healthcare deals: even when states approve mergers, labor-market scrutiny is here to stay.

4. State and Federal Regulators Are Likely Headed for More Public Clashes

The Indiana decision is one more example where states and federal antitrust enforcers have disagreed on hospitals’ consolidation strategies.

The FTC’s public opposition to the deal emphasized:

  • Risk of 10–30% price increases
  • Potential 3–10% increases in insurance premiums
  • Concerns that promised efficiencies and service improvements are often overstated

State regulators, by contrast, emphasized:

  • Financial stability of local hospitals
  • Preservation of service lines
  • Concerns about rural or mid-size markets losing access

This divergence reflects different missions:

  • Federal antitrust law prioritizes competition.
  • State health authorities prioritize access, continuity, and system stability.

Going forward, industry participants should expect more situations where the federal agencies oppose deals but states approve them under COPAs or similar frameworks. This dual-track dynamic complicates deal planning and risk assessment.

5. The Indiana Merger Signals Broader Trends in Hospital Consolidation and State Oversight

Several broader themes emerge from the Indiana approval:

A. States are becoming more active in healthcare M&A oversight.

Indiana recently enacted a healthcare transaction notification law (effective July 2024), requiring notice to the Attorney General for certain deals. Other states, including California, Oregon, Illinois, and Washington, have enacted similar regimes.

B. COPA frameworks may proliferate in rural or financially stressed markets.

Where competition is already limited and hospitals face financial strain, COPAs may become a preferred path to consolidation.

C. States are experimenting with price regulation in a sector increasingly shaped by market power.

The 265%-of-Medicare cap is notable because it directly regulates commercial pricing, something states have been hesitant to do outside of rate review commissions.

D. Private payers may become more politically vocal.

Commercial insurers have long argued that hospital market power drives premium increases. A merger approved with a price cap creates both a benchmark and a political opportunity to push for broader rate regulation.

Conclusion: A Case Study in the Future of Antitrust in Healthcare

The Indiana approval is important not because it is unique, but because it is emblematic. With federal authorities continuing to aggressively scrutinize hospital consolidation, states increasingly serve as alternative forums for evaluating healthcare deals, forums with different priorities, different tools, and different tolerances for risk.

The Indiana merger shows that even a “presumptively anticompetitive” transaction may proceed if the state sees value in preserving local systems and imposing regulatory guardrails. Whether those guardrails work, and whether they can truly substitute for competition, remains a central question for antitrust in healthcare.